Abstract
Objective To determine the therapeutic efficacy of curcumine on inflammatory bowel disease (IBD) and its underlying mechanisms. Methods The rat ulcerative colitis model was developed by using 30 g/L dextran sulfate sodium.Twenty-four young rats were divided into 4 groups: normal group, model group, curcumin 100 mg/kg group(curcumin 100 group), and curcumin 300 mg/kg group(curcumin 300 group). Curcumin was given through gastric gavage once a day for 7 days.General condition, disease activity index (DAI) and histopathological score(HPS) were evaluated.The proportions of CD4+ CD25+Foxp3+ regulatory T cells(Treg) and CD4+ IL-17+ helper T lymphocyte 17(Th17) in CD4+ T cells in rats, and spleen cells were calculated by using flow cytometry.Immunohistochemical method was performed to determine the level of SOCS3 in colon tissues. Results After curcumin administered through gastric gavage for 5 days, compared with the DAI in the model group[(7.50±0.32) scores], HPS in the curcumin 100 group[(4.00±1.10) scores] and the curcumin 300 group [(5.00±0.89) scores] significantly reduced, and the difference was significant(F=12.469, P 0.05). Compared with the model group[(6.5±1.5)%], the propotion of CD4+ CD25+Foxp3+ Treg cells in CD4+ T cells in the curcumin 100 group[(9.9±1.0)%], the curcumin 300 group [(9.3±0.7)%] and the normal group[(9.6±1.1)%]was obviously upregulated(F=16.635, P 0.05). Compared with the model group[(3.5±1.4)%], the propotion of CD4+ IL-17+ Th17 cells in CD4+ T cells in the curcumin 100 group[(2.0±0.9)%], the curcumin 300 group [(1.2±0.6)%] and the normal group[(2.0±0.9)% ] was downregulated(F=5.155, P 0.05). There was no obvious difference between the curcumin 100 group and the curcumin 300 group in these indicators respectively(all P>0.05). Conclusions Curcumin probably attenuates IBD severity, reduces inflammation and regulates the balance of Treg/Th17 through the inhibition of SOCS3 expression. Key words: Inflammatory bowel disease; Curcumine; SOCS3; Regulatory T cells; Helper T lymphocyte 17
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.